1376
HETEROCYCLES, Vol. 77, No. 2, 2009
(d, J = 9 Hz, 4H), 3.79 (s, 6H), 3.44 (s, 4H), 2.45 (s, 8H); 13C NMR (67.8 MHz, CDCl3): δ 158.9, 130.6,
128.5, 113.6, 61.9, 55.1, 52.1. Anal. Calcd for C20H26N2O2: C, 73.59; H, 8.03; N, 8.58. Found: C, 73.37;
H, 7.99; N, 8.40.
N,N’-Bis(p-chlorobenzyl)piperazine (2e): 1H NMR (270 MHz, CDCl3): δ 7.28-7.21 (m, 8H), 3.45 (s, 4H),
13
2.44 (s, 8H); C NMR (67.8 MHz, CDCl3): δ 136.7, 132.6, 130.3, 128.3, 62.1, 52.9. Anal. Calcd for
C18H20Cl2N2: C, 64.48; H, 6.01; N, 8.36. Found: C, 64.18; H, 6.04; N, 8.21.
N,N’-Bis(p-bromobenzyl)piperazine (2f): 1H NMR (270 MHz, CDCl3): δ 7.42 (d, J = 9 Hz, 4H), 7.18 (d,
13
J = 9 Hz, 4H), 3.44 (s, 4H), 2.44 (s, 8H); C NMR (67.8 MHz, CDCl3): δ 137.2, 131.2, 130.7, 120.7,
62.2, 52.9. Anal. Calcd for C18H20Br2N2: C, 50.97; H, 4.75; N, 6.60. Found: C, 50.94; H, 4.67; N, 6.45.
N,N’-Bis(p-trifluoromethylbenzyl)piperazine (2g): 1H NMR (270 MHz, CDCl3):δ 7.56 (d, J = 8 Hz, 4H),
7.44 (d, J = 8 Hz, 4H), 3.56 (s, 4H), 2.48 (s, 8H); 13C NMR (67.8 MHz, CDCl3): δ 142.5, 129.3 (q, J = 32
Hz), 129.2, 125.5 (q, J = 4 Hz), 124.2 (q, J = 270 Hz), 62.4, 53.1. Anal. Calcd for C20H20F6N2: C, 59.70;
H, 5.01; N, 6.96. Found: C, 59.63; H, 5.00; N, 7.02.
General procedure for the N-alkylative cross coupling of Boc-protected diethanolamines (3a-c) with
benzylamine (4) giving N-benzyl-N’-Boc-piperazine derivatives (5a-c) catalyzed by Cp*Ir complex
shown in Eq 2: Under an atmosphere of argon in a heavy-walled glass reactor, 3 (0.50 mmol), 4 (1.5
mmol), [Cp*IrCl2]2 (0.025 mmol, 5.0 mol%), base (0.15 mmol, 30 mol%), and toluene (0.1 mL) were
placed. The reactor was sealed, and the mixture was stirred at 110 °C for 17 h. After analysis by GC,
the products were isolated by silica-gel column chromatography (eluent: hexane-EtOAc).
tert-Butyl 4-benzyl-1-piperazinecarboxylate (5a):14 1H NMR (270 MHz, CDCl3): δ 7.35-7.25 (m, 5H),
3.51 (s, 2H), 3.42 (t, J = 5 Hz, 4H), 2.38 (t, J = 5 Hz, 4H), 1.45 (s, 9H); 13C NMR (67.8 MHz, CDCl3): δ
154.8, 137.8, 129.1, 128.2, 127.1, 79.5, 63.0, 52.8, 28.4.
tert-Butyl 2-methyl-4-benzyl-1-piperazinecarboxylate (5b):15 1H NMR (270 MHz, CDCl3): δ 7.33-7.24
(m, 5H), 4.18 (m, 1H), 3.80 (d, J = 13 Hz, 1H), 3.46 (m, 1H), 3.11 (m, 1H), 2.75 (d, J = 11 Hz, 1H), 2.58
13
(d, J = 11 Hz, 1H), 2.11 (dd, J = 11, 4 Hz, 1H), 2.00 (m, 1H), 1.47 (s, 9H), 1.24 (d, J = 7 Hz, 3H); C
NMR (67.8 MHz, CDCl3): δ 154.8, 138.4, 128.7, 128.2, 127.0, 79.3, 62.8, 57.4, 53.2, 28.4, 15.9.
tert-Butyl 3-methyl-4-benzyl-1-piperazinecarboxylate (5c):16 1H NMR (270 MHz, CDCl3): δ 7.34-7.23
(m, 5H), 4.00 (d, J = 14 Hz, 1H), 3.67-3.62 (m, 2H), 3.18 (d, J = 14 Hz, 1H), 3.10-3.02 (m, 1H), 2.88 (br,
13
1H), 2.66-2.61 (m, 1H), 2.48-2.37 (m, 1H), 2.10-2.04 (m, 1H), 1.45 (s, 9H), 1.12 (d, J = 6 Hz, 3H); C
NMR (67.8 MHz, CDCl3): δ 154.7, 138.7, 128.9, 128.2, 126.9, 79.4, 58.0, 53.1, 50.0, 28.4, 15.3.
REFERENCES
1. (a) S. Liao, J. Alfaro-Lopez, M. D. Shenderovich, K. Hosohata, J. Lin, X. Li, D. Stropova, P. Davis,
K. A. Jernigan, F. Porreca, H. I. Yamamura, and V. J. Hruby, J. Med. Chem., 1998, 41, 4767. (b) D.